The new gene therapies will be used for the treatment of genetic epilepsies and additional central nervous system disorders. Taysha will have an exclusive option on the new payloads, constructs, and intellectual property associated with, and arising from, the research conducted under the agreement.

Researchers at the Cleveland Clinic Lerner Research Institute will create minigene payloads designed to address the limitations of vector packaging capacity in AAV gene therapy. UTSW will create and evaluate vector constructs for in vivo and in vitro efficacy.

Taysha, UTSW start fund to speed up CNS gene therapies
Taysha Gene Therapies and the University of Texas Southwestern Medical Center (UTSW) have launched a fund to accelerate the development of adeno-associated...

AllStripes, Taysha Gene Therapies partner on rare disease gene therapy program
AllStripes and Taysha Gene Therapies have entered a multiyear collaboration focused on advancing the development of TSHA-104, an adeno-associated virus...

Taysha nabs rare pediatric disease, orphan drug status
Taysha Gene Therapies has received rare pediatric disease designation and orphan drug designation from the U.S. Food and Drug Administration for TSHA-104,...

Taysha gets $95M in financing to advance gene therapies
Taysha Gene Therapies has closed on $95 million in series B financing to advance gene therapies for monogenic central nervous system diseases.